AIM: To evaluate the value of endovascular stent in the treatment of portal hypertension caused by benign main portal vein stenosis. METHODS: Portal vein stents were implanted in six patients with benign main portal vein stenosis (inflammatory stenosis in three cases, postprocedure of liver transplantation in another three cases). Changes in portal vein pressure, portal vein patency, relative clinical symptoms, complications, and survival were evaluated. RESULTS: Six metallic stents were successfully placed across the portal vein stenotic or obstructive lesions in six patients. Mean portal venous pressure decreased significantly after stent implantation from (37.3+/-4.7) cm H(2)O to (18.0+/-1.9) cm H(2)O. The portal blood flow restored and the symptoms caused by portal hypertension were eliminated. There were no severe procedure-related complications. The patients were followed up for 1-48 mo. The portal vein remained patent during follow-up. All patients survived except for one patient who died of other complications of liver transplantation. CONCLUSION: Percutaneous portal vein stent placement for the treatment of portal hypertension caused by benign main portal vein stenosis is safe and effective.
AIM: To evaluate the value of endovascular stent in the treatment of portal hypertension caused by benign main portal vein stenosis. METHODS: Portal vein stents were implanted in six patients with benign main portal vein stenosis (inflammatory stenosis in three cases, postprocedure of liver transplantation in another three cases). Changes in portal vein pressure, portal vein patency, relative clinical symptoms, complications, and survival were evaluated. RESULTS: Six metallic stents were successfully placed across the portal vein stenotic or obstructive lesions in six patients. Mean portal venous pressure decreased significantly after stent implantation from (37.3+/-4.7) cm H(2)O to (18.0+/-1.9) cm H(2)O. The portal blood flow restored and the symptoms caused by portal hypertension were eliminated. There were no severe procedure-related complications. The patients were followed up for 1-48 mo. The portal vein remained patent during follow-up. All patients survived except for one patient who died of other complications of liver transplantation. CONCLUSION: Percutaneous portal vein stent placement for the treatment of portal hypertension caused by benign main portal vein stenosis is safe and effective.
Authors: Piotr Malkowski; Jacek Pawlak; Bogdan Michalowicz; Jerzy Szczerban; Tadeusz Wroblewski; Elzbieta Leowska; Marek Krawczyk Journal: Hepatogastroenterology Date: 2003 Nov-Dec
Authors: G Maleux; J Vaninbroukx; C Verslype; D Vanbeckevoort; P Van Hootegem; F Nevens Journal: Cardiovasc Intervent Radiol Date: 2003 Jul-Aug Impact factor: 2.740
Authors: Tae Young Park; Dong Wan Seo; Hyeon-Ji Kang; Min Keun Cho; Tae Jun Song; Do Hyun Park; Sang Soo Lee; Sung Koo Lee; Myung-Hwan Kim Journal: Endosc Ultrasound Date: 2016 Sep-Oct Impact factor: 5.628